IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Rebecca M. Henderson sold 8,790 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $241.57, for a total transaction of $2,123,400.30. Following the sale, the director now owns 27,486 shares of the company’s stock, valued at $6,639,793.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ:IDXX traded up $7.27 during midday trading on Thursday, hitting $253.45. 227,213 shares of the stock traded hands, compared to its average volume of 515,041. The company has a market cap of $21.66 billion, a price-to-earnings ratio of 59.50 and a beta of 0.97. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 14.81. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.04 by $0.13. The firm had revenue of $576.06 million during the quarter, compared to the consensus estimate of $575.04 million. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.01 earnings per share. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 4.82 EPS for the current fiscal year.
Several large investors have recently modified their holdings of the company. Pearl River Capital LLC bought a new position in IDEXX Laboratories in the fourth quarter worth about $28,000. Coastal Investment Advisors Inc. bought a new position in IDEXX Laboratories in the first quarter worth about $37,000. Monetary Management Group Inc. bought a new position in IDEXX Laboratories in the first quarter worth about $45,000. Cresset Asset Management LLC bought a new position in IDEXX Laboratories in the first quarter worth about $63,000. Finally, Anderson Fisher LLC bought a new position in IDEXX Laboratories in the first quarter worth about $70,000. 87.46% of the stock is owned by hedge funds and other institutional investors.
Several analysts have issued reports on IDXX shares. Zacks Investment Research lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, April 3rd. BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. Finally, Canaccord Genuity lowered their price objective on shares of IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a research note on Tuesday, March 26th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. IDEXX Laboratories presently has an average rating of “Buy” and an average price target of $253.50.
TRADEMARK VIOLATION WARNING: “Insider Selling: IDEXX Laboratories, Inc. (IDXX) Director Sells 8,790 Shares of Stock” was first published by Zolmax and is the sole property of of Zolmax. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://zolmax.com/investing/insider-selling-idexx-laboratories-inc-idxx-director-sells-8790-shares-of-stock/3085967.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Read More: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.